Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4690565 | 0.87 | SLC6A2 (0.41) | MEN1KMT2ACACNA1B | |
| SCHEMBL3267607 | 0.78 | GPR119 (0.44) | GPR119 | |
| SCHEMBL653650 | 0.77 | NR1D1 (0.64) | USP30GPR119JAK2JAK1NR1D1 | |
| SCHEMBL27661559 | 0.77 | SLC6A2 (0.53) | USP30GPR119JAK2JAK1 | |
| SCHEMBL5670810 | 0.77 | SLC6A2 (0.53) | USP30GPR119JAK2JAK1 | |
| SCHEMBL5993914 | 0.76 | SLC6A2 (0.59) | GPR119MEN1KMT2A | |
| SCHEMBL5992970 | 0.75 | GPR119 (0.46) | GPR119JAK2JAK1MEN1KMT2A | |
| SCHEMBL5996682 | 0.75 | SLC6A2 (0.59) | GPR119MEN1KMT2A | |
| Acetic Acid SCHEMBL5993263 | 0.74 | SLC6A2 (0.58) | GPR119MEN1KMT2A | |
| SCHEMBL4487331 | 0.74 | CYP1A2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | USP30 4560/4885GPR119 425/4885JAK2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.